Inside Fujifilm's $3 billion drug plant

Industry Trends & Investment - A new $3 billion drug manufacturing plant is opening in North Carolina, potentially at an opportune time for US manufacturing [1][2] - North Carolina was ranked as the top state for business, indicating a favorable environment for manufacturing investments [2] - The new Fujifilm Biotechnologies factory will be one of the largest biologics manufacturing facilities in the US, featuring bioreactors capable of holding 20,000 liters each [2][3] - Historically, the US has lagged behind Europe in biologics production, with only 17% of branded injectable drugs originating in the US compared to almost half in Europe [3] - Pharmaceuticals from the EU will face a 15% tariff, which is lower than previously anticipated, benefiting the industry [4] Impact of Tax Policy - Lower corporate tax rate of 21% is encouraging more US manufacturing investments [5] - The US biopharmaceutical manufacturing landscape has expanded from approximately 1,000 facilities to 1,600 since the 2017 tax act passage [6] Company Specifics - Johnson & Johnson is among the first companies to utilize the new facility, signaling further investments across the country [5] - It takes significant time to realize the benefits of investments, with the new plant taking five years from conception to near-completion [6]